Mode de Salud

CagriSema

CagriSema 10 mg es una combinación para investigación en proporción 1:1 que contiene Cagrilintida (5 mg) y Semaglutida (5 mg). Estos compuestos actúan sobre diferentes vías de los receptores de amilina y GLP-1, y se investigan en conjunto en estudios relacionados con la señalización metabólica, la regulación de la glucosa, la señalización del apetito y el equilibrio energético.

$79.99 USD

Sale Sold out

Shipping calculated at checkout.

mg 10mg

What is CagriSema?

CagriSema is a dual-peptide formulation combining cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. This product contains 5 mg of each compound for a total of 10 mg.

Why are cagrilintide and semaglutide combined?

The two compounds interact with different receptor systems. Researchers study the combination to examine how simultaneous amylin and GLP-1 pathway activation compares with studying either compound individually.

What areas of research involve CagriSema?

Cagrilintide and semaglutide are investigated in research on metabolic signaling, glucose homeostasis, food intake regulation, gastric activity, and body weight regulation.

Medications are not FDA-approved, and the FDA does not review or evaluate compounded products for safety, effectiveness, or quality. Actual product packaging may differ from images or descriptions shown. All treatments are offered only following an online medical consultation and a prescription issued by a licensed healthcare provider. Any referenced benefits are based on third-party studies and are provided for informational purposes only. Individual results may vary.

View full details